PALO ALTO, Calif and RESEARCH TRIANGLE PARK, N.C., Nov. 04, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced recent business highlights and reported financial results for the quarter ended September 30, 2015.
“The third quarter marked a period of significant progress for Ocera and OCR-002,” said Linda Grais, M.D., president and chief executive officer of Ocera. “We have now enrolled over 115 patients in our STOP-HE Phase 2b study of hospitalized patients with acute hepatic encephalopathy (HE). Consistent with previous guidance, we expect to complete full enrollment of approximately 230 patients in the second half of 2016. We also initiated a Phase 1 trial with several oral prototype formulations of OCR-002 in the third quarter, with data expected in the near term.
Help employers find you! Check out all the jobs and post your resume.
